|
gptkbp:instanceOf
|
gptkb:Corticosteroid
synthetic glucocorticoid
|
|
gptkbp:approvalYear
|
1990
|
|
gptkbp:ATCCode
|
R03BA05
R01AD08
|
|
gptkbp:bioavailability
|
0.51% (nasal)
less than 1% (inhaled)
|
|
gptkbp:brand
|
gptkb:Cutivate
gptkb:Flonase
gptkb:Flovent
|
|
gptkbp:CASNumber
|
80474-14-2
|
|
gptkbp:chemicalClass
|
corticosteroid ester
|
|
gptkbp:contraindication
|
hypersensitivity
untreated local infection
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
7.8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C22H27F3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluticasone
|
|
gptkbp:KEGGID
|
D07927
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
glucocorticoid receptor agonist
|
|
gptkbp:meltingPoint
|
273–274 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
91%
|
|
gptkbp:PubChem_CID
|
444036
CHEMBL1200698
DB00588
|
|
gptkbp:riskFactor
|
growth suppression in children (rare)
adrenal suppression (with long-term use)
|
|
gptkbp:routeOfAdministration
|
topical
inhalation
nasal spray
|
|
gptkbp:sideEffect
|
gptkb:oral_candidiasis
headache
hoarseness
throat irritation
nasal irritation
|
|
gptkbp:synonym
|
gptkb:fluticasone_propionate
fluticasone furoate
|
|
gptkbp:UNII
|
0J48LPH2TH
|
|
gptkbp:usedFor
|
asthma
chronic obstructive pulmonary disease
allergic rhinitis
nasal polyps
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|